Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | OTHER |
| Peking University Third Hospital | OTHER |
| Fujian Provincial Hospital | OTHER |
Not provided
Not provided
Not provided
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| D subtype | Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Depleted (D, TSR-low&sTIL-low) |
| |
| F subtype | Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Fibrotic (F, TSR-high&sTIL-low) |
| |
| IE subtpye | Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched, Non-Fibrotic (IE, TSR-low&sTIL-high) |
| |
| IE/F subtype | Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched and Fibrotic (IE/F, TSR-high&sTIL-high) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chemotherapy | Drug | Gemicitabin and cisplatin |
| |
| Immunotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| DFS | Disease-free survival include death and recurrence | 1 year, 3 years and 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| ORR | Response rate | 3 month after the start of treatment until the end of treatment |
| OS | Overall survival | 1 year, 3 years and 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Locally advanced UTUC patients such as pathological diagnosed as UTUC with muscle-invasion stages or lymph nodes metastasis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chunru Doc. Xu, M.D. | Contact | +86-17812172086 | xcrbdyy@126.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
PD-1/PD-L1 |
|
| ADC | Drug | ADC drug like RC48 |
|
| Chemotherapy combined with immunotherapy | Drug | Chemotherapy combined with immunotherapy |
|
| AE | adverse effects | 1-3 months after starting treatment |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D007167 | Immunotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D056747 | Immunomodulation |
| D001691 | Biological Therapy |
Not provided
Not provided